Metropolitan Life Insurance Company (MetLife)’s Spero Therapeutics SPRO Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-6,987	Closed	-$112K	–	2643
2021 Q4	$112K	Hold	6,987	–	–	﹤0.01%	2413
2021 Q3	$129K	Hold	6,987	–	–	﹤0.01%	2373
2021 Q2	$97.5K	Buy	6,987 +1,802	+35%	+$25.2K	﹤0.01%	2600
2021 Q1	$76.3K	Sell	5,185 -1,405	-21%	-$24.7K	﹤0.01%	2484
2020 Q4	$128K	Buy	+6,590	New	+$103K	﹤0.01%	2223
2020 Q3	–	Sell	-5,227	Closed	-$70.7K	–	2590
2020 Q2	$70.7K	Buy	+5,227	New	+$58.7K	﹤0.01%	2433

Other funds holding SPRO

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s SPRO Position: Q1 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Spero Therapeutics (SPRO) in Q1 2022, closing a stake of 6,987 shares — an estimated $112K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in SPRO in Q2 2020 and held it in 6 quarters. The position peaked at $129K in Q3 2021. 100 funds tracked by Wall St. Rank hold SPRO as of Q1 2022.

Metropolitan Life Insurance Company (MetLife) reported no remaining Spero Therapeutics position as of Q1 2022 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 6,987 Spero Therapeutics shares in Q1 2022, an estimated $112K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Spero Therapeutics in Q2 2020 and held it in 6 quarters.
Metropolitan Life Insurance Company (MetLife)'s Spero Therapeutics position peaked at $129K in Q3 2021.
100 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2022, filed 12 May 2022.